Skip to content

Released Nov 8, 2022, before the open

10-Q filed Nov 8, 2022, 39 days after period end · 0001628280-22-028930

Q3 2022 · 10-Q
Revenue$6.63M+16,080.5% vs Q3 2021+47.8% vs Q2 2022
Net Income-$25.77MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.62N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$28,259,000N/M
Operating Cash Flowderived-$19,986,000N/M
Free Cash Flowderived-$20,316,000N/M
Margins · derived
Operating margin-426.0%+63625.2 pt vs Q3 2021
Net margin-388.4%+63221.3 pt vs Q3 2021

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020Q3 2019
Revenue$6.63M$41.00K$179.00K—
Net Income-$25.77M-$26.08M-$18.37M-$13.09M
EPS Diluted-$0.62-$0.71-$3.12-$3.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR